RenovoRx Inc.

RNXT | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.69

+$0.02 (+1.20%)

Sep 22, 2026, 12:11 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.20%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $76.14M

1D Range

1.67 1.73

52W Range

0.70 2.59

Valuation (TTM)

PE -5.22

PB 8.38

EV/EBITDA -5.37

Valuation (NTM)

Forward PE N/A

Forward PEG 0.11

Price Target $8.75

Cash Flow

FCF Yield -15.9%

SBC Adj. FCF Yield -17.9%

SBC Impact -12.7%

Margins

Gross Margin 84.4%

Operating Margin -678.0%

FCF Margin -604.1%

Growth (CAGR)

Revenue 3Y | 5Y 112.4% | 87.5%

Dil EPS 3Y | 5Y 4.3% | 17.7%

FCF 3Y | 5Y -12.6% | -8.2%

Returns

ROA -107.1%

ROE -145.6%

ROIC -139.7%

Financial Health

Net Cash

$9.48M

Current Ratio 5.74

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative dru...

Sector Healthcare

Industry Biotechnology

Employees 17

IPO Date Aug 25, 2021

Website renovorx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$8.75

Upside

+417.75%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞